In The Know-January 2022

January 2022

Pdf Summary

The January 2022 edition of Ed's List: In The Know features several important studies in the field of gynecologic oncology. Here are the key findings from each study:<br /><br />1. Ovarian Cancer Symptoms and Early Diagnosis: A case-control study found that women with ovarian cancer typically had symptoms of more recent onset and experienced their symptoms almost daily compared to women without ovarian cancer. Symptom recognition and appropriate diagnostic testing are important for early diagnosis and improved outcomes.<br /><br />2. Germline BRCA Testing in Ovarian Cancer: Testing rates for germline BRCA variations in ovarian cancer patients with commercial insurance were low, ranging from 14.7% in 2008 to 46.4% in 2018. Testing rates were lower in older women and those with more comorbidities.<br /><br />3. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer: The combination of lenvatinib and pembrolizumab showed significantly longer progression-free survival and overall survival compared to chemotherapy alone in patients with advanced endometrial cancer.<br /><br />4. Reproductive Factors and Ovarian Cancer Survival: There was no association between reproductive factors and survival after an ovarian cancer diagnosis. Reproductive factors are well-established risk factors for ovarian cancer but do not influence survival.<br /><br />5. Improving the Quality of Care for Patients with Ovarian Cancer: A comprehensive resource guide was developed for multidisciplinary cancer practices to improve the quality of care delivery for patients diagnosed with ovarian cancer.<br /><br />6. Global Burden of Cancer: The global burden of cancer, including incidence, mortality, years of life lost, and disability-adjusted life years, has been increasing since 2010. Efforts to prevent and control cancer should be focused on reducing the burden across all socioeconomic groups.<br /><br />7. Detection of Ovarian Cancer: An imaging drug called pafolacianine, marketed as Cytalux, has been approved by the FDA to improve the detection of ovarian cancer during surgery. It binds to folate receptors and illuminates cancerous tissue under fluorescent light.<br /><br />These studies provide valuable insights into ovarian cancer symptoms, diagnostic testing, treatment options, and improvements in healthcare delivery.

Keywords

gynecologic oncology

ovarian cancer symptoms

early diagnosis

germline BRCA testing

advanced endometrial cancer

reproductive factors

ovarian cancer survival

quality of care

global burden of cancer

detection of ovarian cancer